A groundbreaking clinical trial has revealed that adding Johnson & Johnson’s specialized cancer drug, Erleada, to traditional hormone therapy significantly increases the chances of wiping out high-risk localized prostate cancer and cuts the risk of disease progression or death by up to 29%.
31 May 2026-17:15
31 May 2026-17:15
